Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Eli Lilly (NYSE:LLY) and Samsung Biologics have agreed to launch a Gateway Labs partnership in Korea.
The collaboration will create a new facility offering lab space, operational support, and access to Eli Lilly’s global expertise for early stage biotech companies.
This is the first expansion of Eli Lilly’s Gateway Labs R&D incubator outside the U.S., with a focus on Korea’s growing biotech ecosystem.
Eli Lilly, trading at $1,001.35, has had a 5-year return of about 4.5x and a 1-year return of 22.4%. More recently, the stock shows a 7.3% decline year to date and a 5.4% decline over the past month, alongside a 0.6% decline over the last week. In this context, the new partnership with Samsung Biologics adds another dimension to how the company is building its external R&D network.
For investors watching NYSE:LLY, this move reflects a deeper commitment to sourcing ideas and drug candidates from external biotech partners across Asia. The new Korean hub may influence how Lilly accesses early research, structures collaboration models, and supports emerging companies globally over time.
Stay updated on the most important news stories for Eli Lilly by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Eli Lilly.
NYSE:LLY Earnings & Revenue Growth as at Mar 2026
Investor Checklist Quick Assessment
✅ Price vs Analyst Target: At $1,001.35, Eli Lilly trades about 17.6% below the US$1,214.34 analyst consensus target.
✅ Simply Wall St Valuation: Shares are flagged as undervalued, trading around 30.7% below estimated fair value.
❌ Recent Momentum: The 30 day return of about 5.4% decline shows short term weakness despite the new partnership news.
There is only one way to know the right time to buy, sell or hold Eli Lilly. Head to the Simply Wall St’s company report for the latest analysis of Eli Lilly’s Fair Value..
Key Considerations
📊 The Samsung Biologics Gateway Labs partnership strengthens Eli Lilly’s access to early stage biotech ideas from Korea, which could broaden its long term pipeline options.
📊 Watch how management allocates R&D and partnership capital, and whether external collaborations like this show up in future revenue or product announcements.
⚠️ Simply Wall St flags high debt levels and a high proportion of non cash earnings, so pairing this expansion story with balance sheet and earnings quality checks is important.
Dig Deeper
For the full picture including more risks and rewards, check out the complete Eli Lilly analysis. Alternatively, you can check out the community page for Eli Lilly to see how other investors believe this latest news will impact the company’s narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include LLY.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com